Q32 Bio (QTTB) Stock Price, News & Analysis

Company Overview

Q32 Bio is a clinical-stage biotechnology company focused on developing therapies designed to restore immune homeostasis and address diseases driven by immune dysregulation. The company’s approach targets pathways involved in the transforming growth factor beta superfamily, which plays a role in regulating inflammation, tissue repair and immune responses.

Q32 Bio’s lead product candidate is bempikibart, also known as ADX-914, a fully human monoclonal antibody designed to modulate immune activity through selective targeting of the activin receptor type IIA pathway. The company has evaluated bempikibart in clinical studies for inflammatory and autoimmune conditions, including atopic dermatitis and alopecia areata.

The company’s programs are directed toward developing treatments for patients with significant unmet medical needs. Q32 Bio’s operations center on research, clinical development and potential commercialization of its immune-modulating medicines, with clinical activities conducted in accordance with applicable regulatory requirements in the markets where its studies take place.

Key Stats

• Today's Range: $7.80 to $8.36
• 50-Day Range: $8.11 to $16.49
• 52-Week Range: $1.90 to $23.57
• Volume: 678,386 shs
• Average Volume: 1.18 million shs
• Market Capitalization: $241.43 million
• P/E Ratio: 2.70
• Dividend Yield: N/A
• Price Target: $30.60
• Consensus Rating: Moderate Buy

Q32 Bio Stock Analysis - MarketRank™

Q32 Bio scored higher than 72% of companies evaluated by MarketBeat, and ranked 171st out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Q32 Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 5 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Q32 Bio has a consensus price target of $30.60, representing about 277.3% upside from its current price of $8.11.

Amount of Analyst Coverage

Q32 Bio has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Q32 Bio are expected to decrease in the coming year, from ($1.54) to ($1.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Q32 Bio is 2.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of Q32 Bio is 2.70, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.37.

Price to Book Value per Share Ratio

Q32 Bio has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.34% of the float of Q32 Bio has been sold short.

Short Interest Ratio / Days to Cover

Q32 Bio has a short interest ratio ("days to cover") of 5.15.

Change versus previous month

Short interest in Q32 Bio has recently increased by 6.09%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Q32 Bio does not currently pay a dividend.

Dividend Growth

Q32 Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.53

News Sentiment

Q32 Bio has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Q32 Bio this week, compared to 3 articles on an average week.

Search Interest

Only 8 people have searched for QTTB on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Q32 Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Q32 Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $275,144.00 in company stock.

Percentage Held by Insiders

34.46% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

31.32% of the stock of Q32 Bio is held by institutions.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:QTTB
• Previous Symbol: NASDAQ:QTTB
• CIK: 1661998
• Web: www.q32bio.com
• Phone: (781) 999-0232
• Fax: N/A
• Employees: 22
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Q32 Bio: $30.60
• High Price Target: $40.00
• Low Price Target: $14.00
• Potential Upside/Downside: +277.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.00
• Trailing P/E Ratio: 2.70
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $29.82 million
• Net Margins: N/A
• Pretax Margin: 62.87%
• Return on Equity: 50.17%
• Return on Assets: 29.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.30
• Quick Ratio: 20.30

Sales & Book Value

• Annual Sales: $53.74 million
• Price / Sales: 4.49
• Cash Flow: $1.47 per share
• Price / Cash Flow: 5.52
• Book Value: $3.41 per share
• Price / Book: 2.38

Miscellaneous

• Outstanding Shares: 29,770,000
• Free Float: 19,511,000
• Market Cap: $241.43 million
• Optionable: N/A
• Beta: 0.31